Barostim Neo Neuromodulation Device for Heart Failure Wins FDA Approval

CVRx, a Minneapolis, Minnesota company, won FDA approval for the first neuromodulation device designed to address heart failure. Intended as a treatment option for patients with an ejection fraction ≤35% and New York Heart Failure Classification of III or II (with recent history of Class III), the device stimulates the carotid artery and in tu (Read more...)

Full Story →